These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 214233)
21. [Physiological effects of modified LDL on vascular smooth muscle cells in hyperlipidemia]. Takahashi K; Saito Y Nihon Rinsho; 2001 Mar; 59 Suppl 3():572-7. PubMed ID: 11347134 [No Abstract] [Full Text] [Related]
22. Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Cox DA; Cohen ML Pharmacol Rev; 1996 Mar; 48(1):3-19. PubMed ID: 8685247 [TBL] [Abstract][Full Text] [Related]
23. Platelets and chemokines in atherosclerosis: partners in crime. Weber C Circ Res; 2005 Apr; 96(6):612-6. PubMed ID: 15802619 [TBL] [Abstract][Full Text] [Related]
25. Hyperlipidemia and atherosclerosis. Ross R; Harker L Science; 1976 Sep; 193(4258):1094-100. PubMed ID: 822515 [TBL] [Abstract][Full Text] [Related]
26. Role of mast cells in atherosclerosis. Kovanen PT Chem Immunol; 1995; 62():132-70. PubMed ID: 7546279 [No Abstract] [Full Text] [Related]
27. Effects of genetic mechanisms on plasma lipoprotein metabolism and the pathogenesis of atherosclerosis. Kwiterovich PO; Bachorik PS; Chatterjee S Prog Clin Biol Res; 1979; 32():65-112. PubMed ID: 230521 [No Abstract] [Full Text] [Related]
28. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia. Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122 [TBL] [Abstract][Full Text] [Related]
29. Demystifying good high-density lipoprotein from dysfunctional high-density lipoprotein. Drown DJ Prog Cardiovasc Nurs; 2008; 23(4):198-9. PubMed ID: 19067988 [No Abstract] [Full Text] [Related]
30. [The role of modified low-density lipoproteins in physiology and pathology]. Caialo PP; Pliushch HI Fiziol Zh (1994); 2000; 46(2):124-36. PubMed ID: 10867871 [TBL] [Abstract][Full Text] [Related]
31. Is paraoxonase-3 another hdl-associated protein protective against atherosclerosis? La Du BN Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):467-8. PubMed ID: 11304457 [No Abstract] [Full Text] [Related]
33. Low-density lipoprotein and oxidised low-density lipoprotein: their role in the development of atherosclerosis. Hamilton CA Pharmacol Ther; 1997; 74(1):55-72. PubMed ID: 9336016 [TBL] [Abstract][Full Text] [Related]
34. Studies of primate arterial smooth muscle cells in relation to atherosclerosis. Ross R; Glomset J Adv Exp Med Biol; 1974; 43(0):265-79. PubMed ID: 4365790 [No Abstract] [Full Text] [Related]
35. Heparin and the atherosclerotic process. Engelberg H Pharmacol Rev; 1984 Jun; 36(2):91-110. PubMed ID: 6379681 [No Abstract] [Full Text] [Related]
36. The arterial wall and arteriosclerosis [proceedings]. Wissler RW Proc Inst Med Chic; 1977; 31(6):168-70. PubMed ID: 202944 [No Abstract] [Full Text] [Related]
37. Lipoproteins, platelets, and prostaglandins in atherosclerosis. Kuo PT Am Heart J; 1981 Nov; 102(5):949-53. PubMed ID: 7304409 [No Abstract] [Full Text] [Related]
38. A mechanism by which high-density lipoproteins may slow the atherogenic process. Carew TE; Koschinsky T; Hayes SB; Steinberg D Lancet; 1976 Jun; 1(7973):1315-7. PubMed ID: 58308 [TBL] [Abstract][Full Text] [Related]
39. Atherosclerosis--an inflammatory disease. Ross R N Engl J Med; 1999 Jan; 340(2):115-26. PubMed ID: 9887164 [No Abstract] [Full Text] [Related]